Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 47, Issue 9, 2006, Pages 1908-1914

  Niitsu, Nozomi ^a,b   Okamoto, Masataka ^b   Tomita, Naoto ^b   Aoki, Sadao ^b   Tamaru, Jun Ichi ^b   Miura, Ikuo ^b   Hirano, Masami ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Adult Lymphoma Treatment Study Group ALTSG   (Japan)

Author keywords

Advanced stage; BEACOPP regimen; Hodgkin's lymphoma

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEUKEMIA; LIVER TOXICITY; LONG TERM CARE; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; STOMATITIS; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 33750477330     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600688313     Document Type: Article

References (21)

1. Canellos, G and Anderson, J and Propert, K and Nissen, N and Cooper, M and Henderson, E and (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD N Engl J Med, 19, pp. 1478-1484.
2. Loeffler, M and Hasenclever, D and Diehl, V. (1998) Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group Ann Oncol, 9 Suppl 5, pp. S73-S78.
3. Tesch, H and Diehl, V and Lathan, B and Hasenclever, D and Sieber, M and Ruffer, U and (1998) Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: A study of the German Hodgkin's Lymphoma Study Group Blood, 92, pp. 4560-4567.
4. Diehl, V and Franklin, J and Hasenclever, D and Tesch, H and Pfreundschuh, M and Lathan, B and (1998) BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group J Clin Oncol, 16, pp. 3810-3821.
5. Engel, C and Loeffler, M and Schmitz, S and Tesch, H and Diehl, V. (2000) Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group Ann Oncol, 11, pp. 1105-1114.
6. Hasenclever, D and Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease N Engl J Med, 339, pp. 1506-1514.
7. Sieber, M and Engert, A and Diehl, V. (2000) Treatment of Hodgkin's disease: Results and current concepts of the German Hodgkin's Lymphoma Study Group Ann Oncol, 11, pp. S81-S85.
8. Diehl, V and Franklin, J and Pfreundschuh, M and Lathan, B and Paulus, U and Hasenclever, D. (2003) for the German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease N Engl J Med, 348, pp. 2386-2395.
9. Jaffe, E and Harris, N and Stein, H and Vardiman, J.(2001) WHO Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. In. Lyon: IARC Press.
10. Carbone, P and Kaplan, H and Musshoff, K and Smithers, D and Tubiana, M. (1971) Report of the Committee on Hodgkin's Disease Staging Classification Cancer Res, 31, pp. 1860-1861.
11. Diehl, V and Sieber, M and Ruffer, U and Lathan, B and Hasenclever, D and Pfreundschuh, M and (1997) BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group Ann Oncol, 8, pp. 143-148.
12. Armstrong, A and Alexander, F and Cartwright, R and Angus, B and Krajewski, A and Wright, D and (1998) Epstein-Barr virus and Hodgkin's disease: Further evidence for the three disease hypothesis Leukemia, 12, pp. 1272-1276.
13. Kaplan, E and Meier, P. (1958) Nonparametric estimation from incomplete observations J Am Stat Assoc, 53, pp. 457-481.
14. Wilcoxon, F. (1945) Individual comparisons by ranking methods Biometrics Bull, 1, pp. 80-83.
15. Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep, 50, pp. 163-170.
16. Stein, H and Delsol, G and Pileri, S.(2001) Hodgkin lymphoma. In (pp. 237-253). Lyon: IARC Press. World Health Organization Classification of Tumours, Pathology & Genetics, Tumours of Haematopoietic and Lymphoid Tissues
17. Lymphoma Study Group of Japanese Pathologists. (2000) The World Health Organization classification of malignant lymphomas in Japan: Incidence of recently recognized entities Pathol Int, 50, pp. 696-702.
18. Kanavaros, P and Stefanaki, K and Vlachonikolis, J and Eliopoulos, G and Kakolyris, S and Rontogianni, D and (2000) Expression of p53, p. 21/ waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas Histol Histopathol, 15, pp. 445-453.
19. Krappmann, D and Emmerich, F and Kordes, U and Scharschmidt, E and Dorken, B and Scheidereit, C. (1999) Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells Oncogene, 18, pp. 943-953.
20. Jarrett, R and Stark, G and White, J and Alexander, F and Krajewski, A and Freeland, J and (2005) for the Scotland and Newcastle Epidemiology of Hodgkin Disease Study Group. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: A population-based study Blood, 106, pp. 2444-2451.
21. Keegan, T and Glaser, S and Clarke, C and Gulley, M and Craig, F and Digiuseppe, J and (2005) Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: A population-based study J Clin Oncol, 23, pp. 7604-7613.